Advertisement

Surgery Today

, Volume 41, Issue 7, pp 903–907 | Cite as

Plasma high-mobility group box 1 as an indicator of surgical stress

  • Atsushi Osoegawa
  • Tokujiro Yano
  • Takeharu Yamanaka
  • Tetsuzo Tagawa
  • Fumihiro Shoji
  • Ichiro Yoshino
  • Akinobu Taketomi
  • Hiroyuki Ito
  • Yoshihiro Kakeji
  • Yoshihiko Maehara
Original Article

Abstract

Purpose

High-mobility group box 1 (HMGB-1) is a late-phase cytokine, which is released extracellularly in response to systemic inflammation caused by infection, shock, or trauma. We examined the plasma levels of HMGB-1 to clarify its role in surgical stress.

Methods

The subjects of this study were 37 patients who underwent elective general surgery. We measured plasma concentrations of HMGB-1 over time using a quantitative enzyme-linked immunosorbent assay. We then analyzed the relationships between the change in HMGB-1 concentration and perioperative factors, including postoperative complications. Statistical analyses were performed using two-way repeated-measures analysis of variance.

Results

The HMGB-1 level was higher on postoperative day 3 in patients with a prolonged operative time or large intraoperative blood loss (P = 0.048 and P = 0.041, respectively). The HMGB-1 level also remained high over time in patients with postoperative complications (P = 0.037).

Conclusions

These results show that the plasma HMGB-1 level is related to surgical stress such as operative time and blood loss. The level remained high over time in patients with postoperative complication, suggesting progression of the complication.

Key words

Plasma high-mobility group box 1 Surgical stress Perioperative period Postoperative complications 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996;224(5):647–664.PubMedCrossRefGoogle Scholar
  2. 2.
    Sakurai H, Soejima K, Schmalstieg FC, Nozaki M, Traber DL. Inhibition of lung permeability changes after burn and smoke inhalation by an anti-interleukin-8 antibody in sheep. Surg Today 2009;39(5):399–406.PubMedCrossRefGoogle Scholar
  3. 3.
    Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989;243(4894 Pt 1):1056–1059.PubMedCrossRefGoogle Scholar
  4. 4.
    Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285(5425):248–251.PubMedCrossRefGoogle Scholar
  5. 5.
    Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418(6894):191–195.PubMedCrossRefGoogle Scholar
  6. 6.
    Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004;164(3):441–449.PubMedCrossRefGoogle Scholar
  7. 7.
    Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201(7):1135–1143.PubMedCrossRefGoogle Scholar
  8. 8.
    Angus DC, Yang L, Kong L, Kellum JA, Delude RL, Tracey KJ, et al. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 2007;35(4):1061–1067.PubMedCrossRefGoogle Scholar
  9. 9.
    Jungas T, Verbeke P, Darville T, Ojcius DM. Cell death, BAX activation, and HMGB1 release during infection with Chlamydia. Microbes Infect 2004;6(13):1145–1155.PubMedCrossRefGoogle Scholar
  10. 10.
    Andersson U, Erlandsson-Harris H. HMGB1 is a potent trigger of arthritis. J Intern Med 2004;255(3):344–350.PubMedCrossRefGoogle Scholar
  11. 11.
    Mantell LL, Parrish WR, Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 2006;25(1):4–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003;101(7):2652–2660.PubMedCrossRefGoogle Scholar
  13. 13.
    Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002;123(3):790–802.PubMedCrossRefGoogle Scholar
  14. 14.
    Suda K, Kitagawa Y, Ozawa S, Saikawa Y, Ueda M, Abraham E, et al. Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery? Dis Esophagus 2006;19(1):5–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Suda K, Kitagawa Y, Ozawa S, Miyasho T, Okamoto M, Saikawa Y, et al. Neutrophil elastase inhibitor improves postoperative clinical courses after thoracic esophagectomy. Dis Esophagus 2007;20(6):478–486.PubMedCrossRefGoogle Scholar
  16. 16.
    Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun 1991;177(2):814–820.PubMedCrossRefGoogle Scholar
  17. 17.
    Tamakuma S, Ogawa M, Aikawa N, Kubota T, Hirasawa H, Ishizaka A, et al. Relationship between neutrophil elastase and acute lung injury in humans. Pulm Pharmacol Ther 2004;17(5):271–279.PubMedCrossRefGoogle Scholar
  18. 18.
    Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, et al. Variation of HMGB1 expression in breast cancer. Anticancer Res 2001;21(6A):3881–3885.PubMedGoogle Scholar
  19. 19.
    Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 2003;63(9):2188–2193.PubMedGoogle Scholar
  20. 20.
    Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003;104(6):722–727.PubMedCrossRefGoogle Scholar
  21. 21.
    Meyer B, Murua Escobar H, Hauke S, Richter A, Winkler S, Rogalla P, et al. Expression pattern of the HMGB1 gene in sarcomas of the dog. Anticancer Res 2004;24(2B):707–710.PubMedGoogle Scholar
  22. 22.
    Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405(6784):354–360.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Atsushi Osoegawa
    • 1
    • 4
  • Tokujiro Yano
    • 1
  • Takeharu Yamanaka
    • 2
  • Tetsuzo Tagawa
    • 1
  • Fumihiro Shoji
    • 1
  • Ichiro Yoshino
    • 3
  • Akinobu Taketomi
    • 1
  • Hiroyuki Ito
    • 1
  • Yoshihiro Kakeji
    • 1
  • Yoshihiko Maehara
    • 1
  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Division of Cancer StatisticsNational Hospital Organization Kyushu Cancer CenterFukuokaJapan
  3. 3.Department of Thoracic Surgery, Graduate School of MedicineChiba UniversityChibaJapan
  4. 4.Department of SurgeryHiroshima Red Cross Hospital & Atomic-Bomb Survivors HospitalHiroshimaJapan

Personalised recommendations